by Ilona Baraniak
Breast cancer is the most common type of cancer in women worldwide, with nearly 1.3 million new cases each year. It is the fifth most common cancer-related cause of death for women, and current predictions estimate a continuing rise of cases. CDK4/6 inhibitors provide promising options for the treatment of breast cancer. In this article, Ilona Baraniak provides insights into the area of newly approved second generation of CDK4/6 inhibitors.